Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 17.551
Filter
1.
BMJ Open Respir Res ; 11(1)2024 May 03.
Article in English | MEDLINE | ID: mdl-38702073

ABSTRACT

The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung disease characterised by acute and chronic infections, the accumulation of mucus, airway inflammation, structural damage and pulmonary exacerbations. The prevalence of Pseudomonas aeruginosa rises rapidly in the teenage years, and this organism is the most common cause of chronic lung infection in adults with cystic fibrosis (CF). It is associated with an accelerated decline in lung function and premature death. New P. aeruginosa infections are treated with antibiotics to eradicate the organism, while chronic infections require long-term inhaled antibiotic therapy. The prevalence of P. aeruginosa infections has decreased in CF registries since the introduction of CF transmembrane conductance regulator modulators (CFTRm), but clinical observations suggest that chronic P. aeruginosa infections usually persist in patients receiving CFTRm. This indicates that pwCF may still need inhaled antibiotics in the CFTRm era to maintain long-term control of P. aeruginosa infections. Here, we provide an overview of the changing perceptions of P. aeruginosa infection management, including considerations on detection and treatment, the therapy burden associated with inhaled antibiotics and the potential effects of CFTRm on the lung microbiome. We conclude that updated guidance is required on the diagnosis and management of P. aeruginosa infection. In particular, we highlight a need for prospective studies to evaluate the consequences of stopping inhaled antibiotic therapy in pwCF who have chronic P. aeruginosa infection and are receiving CFTRm. This will help inform new guidelines on the use of antibiotics alongside CFTRm.


Subject(s)
Anti-Bacterial Agents , Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Pseudomonas Infections , Pseudomonas aeruginosa , Cystic Fibrosis/complications , Cystic Fibrosis/microbiology , Cystic Fibrosis/drug therapy , Humans , Pseudomonas Infections/drug therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Administration, Inhalation , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Cystic Fibrosis Transmembrane Conductance Regulator/genetics
2.
Pak J Pharm Sci ; 37(1(Special)): 191-197, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38747269

ABSTRACT

synthesis of a pyrazole containing compound was achieved by reacting phenyl hydrazine with (E)-2-((4-bromophenyl) diazinyl)-1-phenylbutane-1,3-dione to produce 4-((4-bromophenyl) diazinyl)-5-methyl-1,3-diphenyl-pyrazole and characterization using mass spectrometer, 1H NMR and 13C NMR. The pharmacological evaluation of the synthesized compound, denoted as (KA5), against Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 29213 and Clostridiums sporogeneses ATCC 19404, indicate that there is no promising antibacterial activity. However, KA5 shows a competitive anticancer activity (IC50: 8.5µM) upon its evaluation against hepatocellular carcinoma cell line (HepG 2) compared to sorafenib (IC50: 4.51µM). Moreover, human skin fibroblast (HSF) was used to investigate the effect of KA5 on normal cell lines, (IC50: 5.53µM). The presented biological evaluations resulted in better understanding of structure-activity relationship for 1, 3, 4-trisubstituted pyrazoles and revealed a great opportunity for more investigations for novel pyrazole-containing anticancer agents.


Subject(s)
Anti-Bacterial Agents , Antineoplastic Agents , Pyrazoles , Pyrazoles/pharmacology , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Humans , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Structure-Activity Relationship , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Hep G2 Cells , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , Sorafenib/pharmacology , Fibroblasts/drug effects , Niacinamide/pharmacology , Niacinamide/analogs & derivatives , Niacinamide/chemical synthesis , Niacinamide/chemistry , Pseudomonas aeruginosa/drug effects , Escherichia coli/drug effects
3.
BMC Microbiol ; 24(1): 164, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38745145

ABSTRACT

BACKGROUND: Multidrug-resistant (MDR) P. aeruginosa is a rising public health concern, challenging the treatment of such a ubiquitous pathogen with monotherapeutic anti-pseudomonal agents. Worryingly, its genome plasticity contributes to the emergence of P. aeruginosa expressing different resistant phenotypes and is now responsible for notable epidemics within hospital settings. Considering this, we aimed to evaluate the synergistic combination of fortimicin with other traditional anti-pseudomonal agents and to analyze the resistome of pan-drug resistant (PDR) isolate. METHODS: Standard methods were used for analyzing the antimicrobial susceptibility tests. The checkerboard technique was used for the in vitro assessment of fortimicin antibiotic combinations against 51 MDR P. aeruginosa and whole genome sequencing was used to determine the resistome of PDR isolate. RESULTS: Out of 51 MDR P. aeruginosa, the highest synergistic effect was recorded for a combination of fortimicin with ß-lactam group as meropenem, ceftazidime, and aztreonam at 71%, 59% and 43%, respectively. Of note, 56.8%, 39.2%, and 37.2% of the tested MDR isolates that had synergistic effects were also resistant to meropenem, ceftazidime, and aztreonam, respectively. The highest additive effects were recorded for combining fortimicin with amikacin (69%) and cefepime (44%) against MDR P. aeruginosa. Resistome analysis of the PDR isolate reflected its association with the antibiotic resistance phenotype. It ensured the presence of a wide variety of antibiotic-resistant genes (ß-lactamases, aminoglycosides modifying enzymes, and efflux pump), rendering the isolate resistant to all clinically relevant anti-pseudomonal agents. CONCLUSION: Fortimicin in combination with classical anti-pseudomonal agents had shown promising synergistic activity against MDR P. aeruginosa. Resistome profiling of PDR P. aeruginosa enhanced the rapid identification of antibiotic resistance genes that are likely linked to the appearance of this resistant phenotype and may pave the way to tackle antimicrobial resistance issues shortly.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Multiple, Bacterial , Drug Synergism , Genome, Bacterial , Microbial Sensitivity Tests , Pseudomonas aeruginosa , Whole Genome Sequencing , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/isolation & purification , Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Humans , Genome, Bacterial/genetics , Pseudomonas Infections/microbiology
4.
Vet Q ; 44(1): 1-9, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38726795

ABSTRACT

Antibiotic-resistant pathogens are a growing global issue, leading to untreatable infectious diseases in both humans and animals. Personalized bacteriophage (phage) therapy, the use of specific anti-bacterial viruses, is currently a leading approach to combat antibiotic-resistant infections. The implementation of phage therapy has primarily been focused on humans, almost neglecting the impact of such infections on the health and welfare of companion animals. Pets also have the potential to spread resistant infections to their owners or the veterinary staff through zoonotic transmission. Here, we showcase personalized phage-antibiotic treatment of a cat with a multidrug-resistant Pseudomonas aeruginosa implant-associated infection post-arthrodesis surgery. The treatment encompassed a tailored combination of an anti-P. aeruginosa phage and ceftazidime, precisely matched to the pathogen. The phage was topically applied to the surgical wound while the antibiotic was administered intramuscularly. After two treatment courses spanning 7 and 3 weeks, the surgical wound, which had previously remained open for five months, fully closed. To the best of our knowledge, this is the first case of personalized phage therapy application in felines, which provides further evidence of the effectiveness of this approach. The successful outcome paves the way for personalized phage-antibiotic treatments against persistent infections therapy in veterinary practice.


Subject(s)
Anti-Bacterial Agents , Cat Diseases , Phage Therapy , Pseudomonas Infections , Pseudomonas aeruginosa , Animals , Cats , Phage Therapy/veterinary , Pseudomonas Infections/veterinary , Pseudomonas Infections/drug therapy , Pseudomonas Infections/therapy , Cat Diseases/therapy , Cat Diseases/drug therapy , Cat Diseases/microbiology , Pseudomonas aeruginosa/drug effects , Anti-Bacterial Agents/therapeutic use , Ceftazidime/therapeutic use , Drug Resistance, Multiple, Bacterial , Bacteriophages
5.
Pathog Dis ; 822024 Feb 07.
Article in English | MEDLINE | ID: mdl-38730561

ABSTRACT

Antibiotic resistance (ATBR) is increasing every year as the overuse of antibiotics (ATBs) and the lack of newly emerging antimicrobial agents lead to an efficient pathogen escape from ATBs action. This trend is alarming and the World Health Organization warned in 2021 that ATBR could become the leading cause of death worldwide by 2050. The development of novel ATBs is not fast enough considering the situation, and alternative strategies are therefore urgently required. One such alternative may be the use of non-thermal plasma (NTP), a well-established antimicrobial agent actively used in a growing number of medical fields. Despite its efficiency, NTP alone is not always sufficient to completely eliminate pathogens. However, NTP combined with ATBs is more potent and evidence has been emerging over the last few years proving this is a robust and highly effective strategy to fight resistant pathogens. This minireview summarizes experimental research addressing the potential of the NTP-ATBs combination, particularly for inhibiting planktonic and biofilm growth and treating infections in mouse models caused by methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa. The published studies highlight this combination as a promising solution to emerging ATBR, and further research is therefore highly desirable.


Subject(s)
Anti-Bacterial Agents , Biofilms , Plasma Gases , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Plasma Gases/pharmacology , Animals , Humans , Biofilms/drug effects , Pseudomonas aeruginosa/drug effects , Mice , Methicillin-Resistant Staphylococcus aureus/drug effects , Drug Resistance, Bacterial , Drug Resistance, Microbial , Pseudomonas Infections/microbiology , Pseudomonas Infections/drug therapy , Disease Models, Animal , Staphylococcal Infections/microbiology , Staphylococcal Infections/drug therapy
6.
PeerJ ; 12: e16708, 2024.
Article in English | MEDLINE | ID: mdl-38715984

ABSTRACT

The present work aimed at differentiating five Amaranthus species from Saudi Arabia according to their morphology and the ability in nanoparticle formulation. Biogenic silver nanoparticles (AgNPs) were synthesized from leaf extracts of the five Amaranthus species and characterized by different techniques. Fourier-transform infrared spectroscopy (FT-IR) was used to identify the phyto-constituents of Amaranthus species. The nanoparticles (NPs) were characterized by UV-visible spectroscopy, dynamic light scattering (DLS), transmission electron microscopy (TEM), and energy-dispersive X-ray spectroscopy (EDX). The antibacterial activity of the synthesized NPs was tested against Staphylococcus aureus, E. coli, Klebsiella pneumoniae and Pseudomonas aeruginosa using the agar well diffusion method. Spherical NPs varying in size and functional groups from the five plant species were demonstrated by TEM, DLS and FTIR analysis, respectively. Variations in NPs characteristics could be related to the phytochemical composition of each Amaranthus species since they play a significant role in the reduction process. EDX confirmed the presence of Ag in plant fabricated AgNPs. Antibacterial activity varied among the species, possibly related to the NPs characteristics. Varied characteristics for the obtained AgNPs may reflect variations in the phytochemical composition type and concentration among Amaranthus species used for their fabrication.


Subject(s)
Amaranthus , Anti-Bacterial Agents , Metal Nanoparticles , Microbial Sensitivity Tests , Plant Extracts , Silver , Amaranthus/chemistry , Metal Nanoparticles/chemistry , Silver/pharmacology , Silver/chemistry , Plant Extracts/pharmacology , Plant Extracts/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Spectroscopy, Fourier Transform Infrared , Humans , Pseudomonas aeruginosa/drug effects , Plant Leaves/chemistry , Escherichia coli/drug effects , Staphylococcus aureus/drug effects , Microscopy, Electron, Transmission , Saudi Arabia , Bacteria/drug effects , Klebsiella pneumoniae/drug effects
7.
Int J Nanomedicine ; 19: 3861-3890, 2024.
Article in English | MEDLINE | ID: mdl-38708178

ABSTRACT

Introduction: Cystic fibrosis (CF) is associated with pulmonary Pseudomonas aeruginosa infections persistent to antibiotics. Methods: To eradicate pseudomonal biofilms, solid lipid nanoparticles (SLNs) loaded with quorum-sensing-inhibitor (QSI, disrupting bacterial crosstalk), coated with chitosan (CS, improving internalization) and immobilized with alginate lyase (AL, destroying alginate biofilms) were developed. Results: SLNs (140-205 nm) showed prolonged release of QSI with no sign of acute toxicity to A549 and Calu-3 cells. The CS coating improved uptake, whereas immobilized-AL ensured >1.5-fold higher uptake and doubled SLN diffusion across the artificial biofilm sputum model. Respirable microparticles comprising SLNs in carbohydrate matrix elicited aerodynamic diameters MMAD (3.54, 2.48 µm) and fine-particle-fraction FPF (65, 48%) for anionic and cationic SLNs, respectively. The antimicrobial and/or antibiofilm activity of SLNs was explored in Pseudomonas aeruginosa reference mucoid/nonmucoid strains as well as clinical isolates. The full growth inhibition of planktonic bacteria was dependent on SLN type, concentration, growth medium, and strain. OD measurements and live/dead staining proved that anionic SLNs efficiently ceased biofilm formation and eradicated established biofilms, whereas cationic SLNs unexpectedly promoted biofilm progression. AL immobilization increased biofilm vulnerability; instead, CS coating increased biofilm formation confirmed by 3D-time lapse confocal imaging. Incubation of SLNs with mature biofilms of P. aeruginosa isolates increased biofilm density by an average of 1.5-fold. CLSM further confirmed the binding and uptake of the labeled SLNs in P. aeruginosa biofilms. Considerable uptake of CS-coated SLNs in non-mucoid strains could be observed presumably due to interaction of chitosan with LPS glycolipids in the outer cell membrane of P. aeruginosa. Conclusion: The biofilm-destructive potential of QSI/SLNs/AL inhalation is promising for site-specific biofilm-targeted interventional CF therapy. Nevertheless, the intrinsic/extrinsic fundamentals of nanocarrier-biofilm interactions require further investigation.


Subject(s)
Anti-Bacterial Agents , Biofilms , Chitosan , Liposomes , Nanoparticles , Pseudomonas Infections , Pseudomonas aeruginosa , Biofilms/drug effects , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/physiology , Humans , Pseudomonas Infections/drug therapy , Nanoparticles/chemistry , Chitosan/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacokinetics , Drug Carriers/chemistry , Cystic Fibrosis/drug therapy , Cystic Fibrosis/microbiology , Lipids/chemistry , Lipids/pharmacology , Quorum Sensing/drug effects , A549 Cells , Alginates/chemistry
8.
J Biosci ; 492024.
Article in English | MEDLINE | ID: mdl-38726825

ABSTRACT

Bacterial species referred to as magnetotactic bacteria (MTB) biomineralize iron oxides and iron sulphides inside the cell. Bacteria can arrange themselves passively along geomagnetic field lines with the aid of these iron components known as magnetosomes. In this study, magnetosome nanoparticles, which were obtained from the taxonomically identified MTB isolate Providencia sp. PRB-1, were characterized and their antibacterial activity was evaluated. An in vitro test showed that magnetosome nanoparticles significantly inhibited the growth of Staphylococcus sp., Pseudomonas aeruginosa, and Klebsiella pneumoniae. Magnetosomes were found to contain cuboidal iron crystals with an average size of 42 nm measured by particle size analysis and scanning electron microscope analysis. The energy dispersive X-ray examination revealed that Fe and O were present in the extracted magnetosomes. The extracted magnetosome nanoparticles displayed maximum absorption at 260 nm in the UV-Vis spectrum. The distinct magnetite peak in the Fourier transform infrared (FTIR) spectroscopy spectra was observed at 574.75 cm-1. More research is needed into the intriguing prospect of biogenic magnetosome nanoparticles for antibacterial applications.


Subject(s)
Anti-Bacterial Agents , Magnetosomes , Providencia , Pseudomonas aeruginosa , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/isolation & purification , Pseudomonas aeruginosa/drug effects , Magnetosomes/chemistry , Magnetosomes/metabolism , Providencia/chemistry , Providencia/drug effects , Spectroscopy, Fourier Transform Infrared , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/growth & development , Nanoparticles/chemistry , Microbial Sensitivity Tests , Staphylococcus/drug effects , Staphylococcus/growth & development , Particle Size , Iron/chemistry , Iron/metabolism , Magnetite Nanoparticles/chemistry
9.
Sci Rep ; 14(1): 10224, 2024 05 03.
Article in English | MEDLINE | ID: mdl-38702368

ABSTRACT

The biosynthesis of nanoparticles offers numerous advantages, including ease of production, cost-effectiveness, and environmental friendliness. In our research, we focused on the bioformation of silver nanoparticles (AgNPs) using a combination of Lactobacillus sp. and Bacillus sp. growth. These AgNPs were then evaluated for their biological activities against multidrug-resistant bacteria. Our study involved the isolation of Bacillus sp. from soil samples and Lactobacillus sp. from raw milk in Dhamar Governorate, Yemen. The synthesized AgNPs were characterized using various techniques such as UV-visible spectroscopy, X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), and transmission electron microscopy (TEM). The antibacterial properties of the AgNPs were assessed using the modified Kirby Bauer disk diffusion method against multidrug-resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa. Our results demonstrated that the use of a bacterial mixture for biosynthesis led to faster and more effective production of AgNPs compared to using a single bacterium. The UV-visible spectra showed characteristic peaks indicative of silver nanoparticles, while XRD analysis confirmed the crystalline nature of the synthesized particles. FTIR results suggested the presence of capping proteins that contribute to the synthesis and stability of AgNPs. Furthermore, TEM images revealed the size and morphology of the AgNPs, which exhibited spherical shapes with sizes ranging from 4.65 to 22.8 nm. Notably, the antibacterial activity of the AgNPs was found to be more pronounced against Staphylococcus aureus than Pseudomonas aeruginosa, indicating the potential of these nanoparticles as effective antimicrobial agents. Overall, our study highlights the promising antibacterial properties of AgNPs synthesized by a mixture of Lactobacillus sp. and Bacillus sp. growth. Further research is warranted to explore the potential of utilizing different bacterial combinations for enhanced nanoparticle synthesis.


Subject(s)
Anti-Bacterial Agents , Bacillus , Lactobacillus , Metal Nanoparticles , Microbial Sensitivity Tests , Silver , Metal Nanoparticles/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/biosynthesis , Silver/chemistry , Silver/pharmacology , Bacillus/metabolism , Lactobacillus/metabolism , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/growth & development , Staphylococcus aureus/drug effects , Staphylococcus aureus/growth & development , Spectroscopy, Fourier Transform Infrared , X-Ray Diffraction
10.
Sci Rep ; 14(1): 10200, 2024 05 03.
Article in English | MEDLINE | ID: mdl-38702397

ABSTRACT

Today, antibiotic therapies that previously worked well against certain bacteria due to their natural sensitivity, are becoming less effective. Honey has been proven to inhibit the biofilm formation of some respiratory bacteria, however few data are available on how the storage time affects the antibacterial effect. The activity of black locust, goldenrod, linden and sunflower honeys from three consecutive years (2020, 2021, 2022) was analyzed in 2022 against Gram-negative (Haemophilus influenzae, H. parainfluenzae, Pseudomonas aeruginosa) and Gram-positive (Streptococcus pneumoniae) bacteria using in vitro microbiological methods. After determining the physicochemical parameters of honey, broth microdilution was applied to determine the minimum inhibitory concentration of each honey type against each bacterium, and crystal violet assay was used to test their antibiofilm effect. The possible mechanism of action was explored with membrane degradation test, while structural changes were illustrated with scanning electron microscopy. Honeys stored for one or two years were darker than fresh honeys, while older honeys had significantly lower antibacterial activity. The most remarkable inhibitory effect was exerted by linden and sunflower honeys, and P. aeruginosa proved to be the most resistant bacterium. Based on our results, honey intended for medicinal purposes should be used as fresh as possible during a treatment.


Subject(s)
Anti-Bacterial Agents , Honey , Microbial Sensitivity Tests , Honey/analysis , Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Biofilms/growth & development , Time Factors , Pseudomonas aeruginosa/drug effects , Food Storage/methods , Humans
11.
BMC Biotechnol ; 24(1): 28, 2024 May 04.
Article in English | MEDLINE | ID: mdl-38702622

ABSTRACT

Scientists know very little about the mechanisms underlying fish skin mucus, despite the fact that it is a component of the immune system. Fish skin mucus is an important component of defence against invasive infections. Recently, Fish skin and its mucus are gaining interest among immunologists. Characterization was done on the obtained silver nanoparticles Ag combined with Clarias gariepinus catfish epidermal mucus proteins (EMP-Ag-NPs) through UV-vis, FTIR, XRD, TEM, and SEM. Ag-NPs ranged in size from 4 to 20 nm, spherical in form and the angles were 38.10°, 44.20°, 64.40°, and 77.20°, Where wavelength change after formation of EMP-Ag-NPs as indicate of dark brown, the broad band recorded at wavelength at 391 nm. Additionally, the antimicrobial, antibiofilm and anticancer activities of EMP-Ag-NPs was assessed. The present results demonstrate high activity against unicellular fungi C. albicans, followed by E. faecalis. Antibiofilm results showed strong activity against both S. aureus and P. aeruginosa pathogens in a dose-dependent manner, without affecting planktonic cell growth. Also, cytotoxicity effect was investigated against normal cells (Vero), breast cancer cells (Mcf7) and hepatic carcinoma (HepG2) cell lines at concentrations (200-6.25 µg/mL) and current results showed highly anticancer effect of Ag-NPs at concentrations 100, 5 and 25 µg/mL exhibited rounding, shrinkage, deformation and granulation of Mcf7 and HepG2 with IC50 19.34 and 31.16 µg/mL respectively while Vero cells appeared rounded at concentration 50 µg/mL and normal shape at concentration 25, 12.5 and 6.25 µg/ml with IC50 35.85 µg/mL. This study evidence the potential efficacy of biologically generated Ag-NPs as a substitute medicinal agent against harmful microorganisms. Furthermore, it highlights their inhibitory effect on cancer cell lines.


Subject(s)
Biofilms , Catfishes , Metal Nanoparticles , Silver , Metal Nanoparticles/chemistry , Biofilms/drug effects , Biofilms/growth & development , Silver/chemistry , Silver/pharmacology , Animals , Humans , Mucus/metabolism , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Vero Cells , Fish Proteins/pharmacology , Fish Proteins/chemistry , Fish Proteins/metabolism , Chlorocebus aethiops , Cell Line, Tumor , Microbial Sensitivity Tests , Pseudomonas aeruginosa/drug effects , Anti-Infective Agents/pharmacology , Anti-Infective Agents/chemistry , Staphylococcus aureus/drug effects , Staphylococcus aureus/physiology , Candida albicans/drug effects , Epidermis/metabolism
12.
BMC Microbiol ; 24(1): 152, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38702660

ABSTRACT

BACKGROUND: Pseudomonas aeruginosa is a common cause of nosocomial infections. However, the emergence of multidrug-resistant strains has complicated the treatment of P. aeruginosa infections. While polymyxins have been the mainstay for treatment, there is a global increase in resistance to these antibiotics. Therefore, our study aimed to determine the prevalence and molecular details of colistin resistance in P. aeruginosa clinical isolates collected between June 2019 and May 2023, as well as the genetic linkage of colistin-resistant P. aeruginosa isolates. RESULTS: The resistance rate to colistin was 9% (n = 18) among P. aeruginosa isolates. All 18 colistin-resistant isolates were biofilm producers and carried genes associated with biofilm formation. Furthermore, the presence of genes encoding efflux pumps, TCSs, and outer membrane porin was observed in all colistin-resistant P. aeruginosa strains, while the mcr-1 gene was not detected. Amino acid substitutions were identified only in the PmrB protein of multidrug- and colistin-resistant strains. The expression levels of mexA, mexC, mexE, mexY, phoP, and pmrA genes in the 18 colistin-resistant P. aeruginosa strains were as follows: 88.8%, 94.4%, 11.1%, 83.3%, 83.3%, and 38.8%, respectively. Additionally, down-regulation of the oprD gene was observed in 44.4% of colistin-resistant P. aeruginosa strains. CONCLUSION: This study reports the emergence of colistin resistance with various mechanisms among P. aeruginosa strains in Ardabil hospitals. We recommend avoiding unnecessary use of colistin to prevent potential future increases in colistin resistance.


Subject(s)
Anti-Bacterial Agents , Bacterial Proteins , Colistin , Microbial Sensitivity Tests , Pseudomonas Infections , Pseudomonas aeruginosa , Transcription Factors , Colistin/pharmacology , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Anti-Bacterial Agents/pharmacology , Humans , Bacterial Proteins/genetics , Pseudomonas Infections/microbiology , Pseudomonas Infections/epidemiology , Prevalence , Drug Resistance, Multiple, Bacterial/genetics , Biofilms/drug effects , Biofilms/growth & development , Hospitals , Drug Resistance, Bacterial/genetics , Cross Infection/microbiology , Cross Infection/epidemiology , Membrane Transport Proteins/genetics , Porins/genetics
13.
J Oleo Sci ; 73(5): 787-799, 2024.
Article in English | MEDLINE | ID: mdl-38692900

ABSTRACT

Launaea sarmentosa, also known as Sa Sam Nam, is a widely used remedy in Vietnamese traditional medicine and cuisine. However, the chemical composition and bioactivity of its essential oil have not been elucidated yet. In this study, we identified 40 compounds (98.6% of total peak area) in the essential oil via GC-MS analysis at the first time. Among them, five main compounds including Thymohydroquinone dimethyl ether (52.4%), (E)-α-Atlantone (9.0%), Neryl isovalerate (6.6%), Davanol D2 (isomer 2) (3.9%), and trans-Sesquisabinene hydrate (3.9%) have accounted for 75.8% of total peak area. The anti-bacterial activity of the essential oil against 4 microorganisms including Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa has also investigated via agar well diffusion assay. The results showed that the essential oil exhibited a strong antibacterial activity against Bacillus subtilis with the inhibition zones ranging from 8.2 to 18.7 mm. To elucidate the anti-bacterial effect mechanism of the essential oil, docking study of five main compounds of the essential oil (Thymohydroquinone dimethyl ether, (E)-α-Atlantone, Neryl isovalerate, Davanol D2 (isomer 2), and trans-Sesquisabinene hydrate) against some key proteins for bacterial growth such as DNA gyrase B, penicillin binding protein 2A, tyrosyl-tRNA synthetase, and dihydrofolate reductase were performed. The results showed that the main constituents of essential oil were highly bound with penicillin binding protein 2A with the free energies ranging -27.7 to -44.8 kcal/mol, which suggests the relationship between the antibacterial effect of essential oil and the affinity of main compounds with penicillin binding protein. In addition, the free energies of main compounds of the essential oil with human cyclooxygenase 1, cyclooxygenase 2, and phospholipase A2, the crucial proteins related with inflammatory response were less than diclofenac, a non-steroidal antiinflammatory drug. These findings propose the essential oil as a novel and promising anti-bacterial and anti-inflammatory medicine or cosmetic products.


Subject(s)
Anti-Bacterial Agents , Bacillus subtilis , Hemiterpenes , Molecular Docking Simulation , Oils, Volatile , Pentanoic Acids , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/chemistry , Oils, Volatile/pharmacology , Oils, Volatile/chemistry , Oils, Volatile/isolation & purification , Bacillus subtilis/drug effects , Staphylococcus aureus/drug effects , Pseudomonas aeruginosa/drug effects , Escherichia coli/drug effects , Tetrahydrofolate Dehydrogenase/metabolism , DNA Gyrase/metabolism , Sesquiterpenes/isolation & purification , Sesquiterpenes/pharmacology , Microbial Sensitivity Tests , Gas Chromatography-Mass Spectrometry
14.
Int J Mol Sci ; 25(9)2024 May 06.
Article in English | MEDLINE | ID: mdl-38732269

ABSTRACT

New antimicrobial molecules effective against Pseudomonas aeruginosa, known as an antibiotic-resistant "high-priority pathogen", are urgently required because of its ability to develop biofilms related to healthcare-acquired infections. In this study, for the first time, the anti-biofilm and anti-virulence activities of a polyphenolic extract of extra-virgin olive oil as well as purified oleocanthal and oleacein, toward P. aeruginosa clinical isolates were investigated. The main result of our study was the anti-virulence activity of the mixture of oleacein and oleocanthal toward multidrug-resistant and intermediately resistant strains of P. aeruginosa isolated from patients with ventilator-associated pneumonia or surgical site infection. Specifically, the mixture of oleacein (2.5 mM)/oleocanthal (2.5 mM) significantly inhibited biofilm formation, alginate and pyocyanin production, and motility in both P. aeruginosa strains (p < 0.05); scanning electron microscopy analysis further evidenced its ability to inhibit bacterial cell adhesion as well as the production of the extracellular matrix. In conclusion, our results suggest the potential application of the oleacein/oleocanthal mixture in the management of healthcare-associated P. aeruginosa infections, particularly in the era of increasing antimicrobial resistance.


Subject(s)
Aldehydes , Anti-Bacterial Agents , Biofilms , Cyclopentane Monoterpenes , Olive Oil , Phenols , Pseudomonas aeruginosa , Biofilms/drug effects , Biofilms/growth & development , Pseudomonas aeruginosa/drug effects , Olive Oil/chemistry , Olive Oil/pharmacology , Phenols/pharmacology , Phenols/chemistry , Aldehydes/pharmacology , Aldehydes/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Humans , Microbial Sensitivity Tests , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Bacterial Adhesion/drug effects
15.
Microbiology (Reading) ; 170(5)2024 May.
Article in English | MEDLINE | ID: mdl-38739119

ABSTRACT

Introduction. Bacterial keratitis, particularly caused by Pseudomonas aeruginosa, is challenging to treat because of multi-drug tolerance, often associated with the formation of biofilms. Antibiotics in development are typically evaluated against planktonic bacteria in a culture medium, which may not accurately represent the complexity of infections in vivo.Hypothesis/Gap Statement. Developing a reliable, economic ex vivo keratitis model that replicates some complexity of tissue infections could facilitate a deeper understanding of antibiotic efficacy, thus aiding in the optimization of treatment strategies for bacterial keratitis.Methodology. Here we investigated the efficacy of three commonly used antibiotics (gentamicin, ciprofloxacin and meropenem) against Pseudomonas aeruginosa cytotoxic strain PA14 and invasive strain PA01 using an ex vivo porcine keratitis model.Results. Both strains of P. aeruginosa were susceptible to the MIC of the three tested antibiotics. However, significantly higher concentrations were necessary to inhibit bacterial growth in the minimum biofilm eradication concentration (MBEC) assay, with both strains tolerating concentrations greater than 512 mg l-1 of meropenem. When MIC and higher concentrations than MBEC (1024 mg l-1) of antibiotics were applied, ciprofloxacin exhibited the highest potency against both P. aeruginosa strains, followed by meropenem, while gentamicin showed the least potency. Despite this, none of the antibiotic concentrations used effectively cleared the infection, even after 18 h of continuous exposure.Conclusions. Further exploration of antibiotic concentrations and aligning dosing with clinical studies to validate the model is needed. Nonetheless, our ex vivo porcine keratitis model could be a valuable tool for assessing antibiotic efficacy.


Subject(s)
Anti-Bacterial Agents , Biofilms , Ciprofloxacin , Disease Models, Animal , Keratitis , Microbial Sensitivity Tests , Pseudomonas Infections , Pseudomonas aeruginosa , Animals , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/growth & development , Anti-Bacterial Agents/pharmacology , Swine , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Biofilms/drug effects , Keratitis/microbiology , Keratitis/drug therapy , Ciprofloxacin/pharmacology , Gentamicins/pharmacology , Meropenem/pharmacology
16.
Exp Clin Transplant ; 22(4): 300-306, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38742321

ABSTRACT

OBJECTIVES: In this study, we analyzed the effects of carbapenem-resistant Pseudomonas aeruginosa infection and mixed infection on the perioperative prognosis of lung transplant recipients and studied statistics on antibiotic resistance in P aeruginosa. MATERIALS AND METHODS: This was a retrospective casecontrol study. We collected data on lung transplant recipients with combined lower respiratory tract P aeruginosa infection within 48 hours after lung transplant at the China-Japan Friendship Hospital from August 2018 to April 2022. We grouped recipients according to P aeruginosa resistance to carbapenem antibiotics and summarized the clinical characteristics of carbapenem-resistant P aeruginosa infection. We analyzed the effects of carbapenemresistant P aeruginosa infection and mixed infections on all-cause mortality 30 days after lung transplant by Cox regression. We used the Kaplan-Meier method to plot survival curves. RESULTS: Patients in the carbapenem-resistant P aeruginosa group had a higher all-cause mortality rate than those in the carbapenem-sensitive P aeruginosa group at both 7 days (6 patients [22.3%] vs 2 patients [4.5%]; P = .022) and 30 days (12 patients [44.4%] vs 7 patients [15.9%]; P = .003) after lung transplant. In multivariate analysis, both carbapenemresistant P aeruginosa infection and P aeruginosa combined with bacterial infection were independent risk factors for death 30 days after transplant in lung transplant recipients (P < .05). In subgroup analysis, carbapenem-resistant P aeruginosa combined with bacterial infection increased the risk of death 30 days after transplant in lung transplant recipients compared with carbapenem-sensitive P aeruginosa combined with bacterial infection (12 patients [60%] vs 6 patients [19.4%]; P < .001). CONCLUSIONS: Combined lower respiratory tract carbapenem-resistant P aeruginosa infection and P aeruginosa combined with bacterial infection early after lung transplant increased the risk of 30-day mortality after lung transplant.


Subject(s)
Anti-Bacterial Agents , Carbapenems , Coinfection , Lung Transplantation , Pseudomonas Infections , Pseudomonas aeruginosa , Humans , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Retrospective Studies , Pseudomonas Infections/mortality , Pseudomonas Infections/microbiology , Pseudomonas Infections/diagnosis , Pseudomonas Infections/drug therapy , Risk Factors , Lung Transplantation/adverse effects , Lung Transplantation/mortality , Carbapenems/pharmacology , Female , Male , Middle Aged , Time Factors , Anti-Bacterial Agents/therapeutic use , Adult , Treatment Outcome , Risk Assessment , beta-Lactam Resistance
17.
Molecules ; 29(9)2024 Apr 25.
Article in English | MEDLINE | ID: mdl-38731451

ABSTRACT

A novel second-generation blue fluorescent polyamidoamine dendrimer peripherally modified with sixteen 4-N,N-dimethylaninoethyloxy-1,8-naphthalimide units was synthesized. Its basic photophysical characteristics were investigated in organic solvents of different polarity. It was found that in these solvents, the dendrimer is colorless and emitted blue fluorescence with different intensities depending on their polarity. The effect of the pH of the medium on the fluorescence intensity was investigated and it was found that in the acidic medium, the fluorescence is intense and is quenched in the alkaline medium. The ability of the dendrimer to detect metal ions (Pb2+, Zn2+, Mg2+, Sn2+, Ba2+, Ni2+, Sn2+, Mn2+, Co2+, Fe3+, and Al3+) was also investigated, and it was found that in the presence of Fe3+, the fluorescent intensity was amplified more than 66 times. The antimicrobial activity of the new compound has been tested in vitro against Gram-positive B. cereus and Gram-negative P. aeruginosa. The tests were performed in the dark and after irradiation with visible light. The antimicrobial activity of the compound enhanced after light irradiation and B. cereus was found slightly more sensitive than P. aeruginosa. The increase in antimicrobial activity after light irradiation is due to the generation of singlet oxygen particles, which attack bacterial cell membranes.


Subject(s)
Dendrimers , Microbial Sensitivity Tests , Naphthalimides , Polyamines , Naphthalimides/chemistry , Naphthalimides/pharmacology , Dendrimers/chemistry , Dendrimers/pharmacology , Polyamines/chemistry , Polyamines/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Fluorescence , Pseudomonas aeruginosa/drug effects , Hydrogen-Ion Concentration , Bacillus cereus/drug effects , Light , Fluorescent Dyes/chemistry , Spectrometry, Fluorescence
18.
Molecules ; 29(9)2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38731501

ABSTRACT

Bacterial infection is a thorny problem, and it is of great significance to developing green and efficient biological antibacterial agents that can replace antibiotics. This study aimed to rapidly prepare a new type of green antibacterial nanoemulsion containing silver nanoparticles in one step by using Blumea balsamifera oil (BBO) as an oil phase and tea saponin (TS) as a natural emulsifier and reducing agent. The optimum preparation conditions of the AgNPs@BBO-TS NE were determined, as well as its physicochemical properties and antibacterial activity in vitro being investigated. The results showed that the average particle size of the AgNPs@BBO-TS NE was 249.47 ± 6.23 nm, the PDI was 0.239 ± 0.003, and the zeta potential was -35.82 ± 4.26 mV. The produced AgNPs@BBO-TS NE showed good stability after centrifugation and 30-day storage. Moreover, the AgNPs@BBO-TS NE had an excellent antimicrobial effect on Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. These results demonstrated that the AgNPs@BBO-TS NE produced in this study can be used as an efficient and green antibacterial agent in the biomedical field.


Subject(s)
Anti-Bacterial Agents , Emulsions , Green Chemistry Technology , Metal Nanoparticles , Microbial Sensitivity Tests , Particle Size , Silver , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Silver/chemistry , Silver/pharmacology , Metal Nanoparticles/chemistry , Staphylococcus aureus/drug effects , Plant Oils/chemistry , Plant Oils/pharmacology , Pseudomonas aeruginosa/drug effects , Escherichia coli/drug effects , Escherichia coli/growth & development , Saponins/chemistry , Saponins/pharmacology
19.
Molecules ; 29(9)2024 May 01.
Article in English | MEDLINE | ID: mdl-38731582

ABSTRACT

Clinicians often have to face infections caused by microorganisms that are difficult to eradicate due to their resistance and/or tolerance to antimicrobials. Among these pathogens, Pseudomonas aeruginosa causes chronic infections due to its ability to form biofilms on medical devices, skin wounds, ulcers and the lungs of patients with Cystic Fibrosis. In this scenario, the plant world represents an important reservoir of natural compounds with antimicrobial and/or antibiofilm properties. In this study, an extract from the leaves of Combretum micranthum G. Don, named Cm4-p, which was previously investigated for its antimicrobial activities, was assayed for its capacity to inhibit biofilm formation and/or to eradicate formed biofilms. The model strain P. aeruginosa PAO1 and its isogenic biofilm hyperproducer derivative B13 were treated with Cm4-p. Preliminary IR, UV-vis, NMR, and mass spectrometry analyses showed that the extract was mainly composed of catechins bearing different sugar moieties. The phytocomplex (3 g/L) inhibited the biofilm formation of both the PAO1 and B13 strains in a significant manner. In light of the obtained results, Cm4-p deserves deeper investigations of its potential in the antimicrobial field.


Subject(s)
Anti-Bacterial Agents , Biofilms , Catechin , Combretum , Microbial Sensitivity Tests , Plant Extracts , Pseudomonas aeruginosa , Biofilms/drug effects , Pseudomonas aeruginosa/drug effects , Plant Extracts/pharmacology , Plant Extracts/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Catechin/pharmacology , Catechin/chemistry , Combretum/chemistry , Plant Leaves/chemistry , Sugars , Humans
20.
Artif Cells Nanomed Biotechnol ; 52(1): 261-269, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38696143

ABSTRACT

The widespread dissemination of bacterial resistance has led to great attention being paid to finding substitutes for traditionally used antibiotics. Plants are rich in various phytochemicals that could be used as antibacterial therapies. Here, we elucidate the phytochemical profile of Euphorbia canariensis ethanol extract (EMEE) and then elucidate the antibacterial potential of ECEE against Pseudomonas aeruginosa clinical isolates. ECEE showed minimum inhibitory concentrations ranging from 128 to 512 µg/mL. The impact of ECEE on the biofilm-forming ability of the tested isolates was elucidated using crystal violet assay and qRT-PCR to study its effect on the gene expression level. ECEE exhibited antibiofilm potential, which resulted in a downregulation of the expression of the biofilm genes (algD, pelF, and pslD) in 39.13% of the tested isolates. The antibacterial potential of ECEE was studied in vivo using a lung infection model in mice. A remarkable improvement was observed in the ECEE-treated group, as revealed by the histological and immunohistochemical studies. Also, ELISA showed a noticeable decrease in the oxidative stress markers (nitric oxide and malondialdehyde). The gene expression of the proinflammatory marker (interleukin-6) was downregulated, while the anti-inflammatory biomarker was upregulated (interleukin-10). Thus, clinical trials should be performed soon to explore the potential antibacterial activity of ECEE, which could help in our battle against resistant pathogenic bacteria.


Subject(s)
Anti-Bacterial Agents , Euphorbia , Plant Extracts , Pseudomonas aeruginosa , Respiratory Tract Infections , Pseudomonas aeruginosa/drug effects , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Euphorbia/chemistry , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Respiratory Tract Infections/drug therapy , Animals , Mice , Oxidative Stress/drug effects , Bacterial Load/drug effects , Gene Expression Regulation, Bacterial/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...